EMJ Podcast: Insights For Healthcare Professionals

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care.

00:22 – Mortality Patterns

08:57 – JAK Inhibitors

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care

01:49 – Polymyalgia Rheumatica

05:59 – Vascular Ultrasound

09:11 – Immune Ageing

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Joan Carles, Head of Section for the Genitourinary, Central Nervous System, Sarcomas and Tumours of Unknown Origin Unit at Vall d'Hebron University Hospital. Carles discusses breakthroughs in genitourinary cancer and sarcoma treatment, including anti-angiogenic therapies, overcoming resistance, and the role of genetic polymorphisms in personalised medicine.

Timestamps:

00:00 – Introduction

01:56 – Anti-angiogenic therapies

05:03 – Treatment resistance

07:53 – Genetic polymorphisms

09:02 – Sarcoma treatments

11:16 – Novel drugs

15:22 – Oncology societies

18:00 – Carles' three wishes for healthcare

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.

Uncover:

· The importance of patient phenotyping: How can biomarkers and imaging improve asthma management?

· Mucus plugging and airflow obstruction: What does the latest research reveal?

· Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling?

· The role of imaging in clinical practice: How can CT scans provide new insights into asthma care?

Speakers

Mario Castro, University of Kansas School of Medicine, United States

Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States

Disclaimers:

· This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.

· The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program

· The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits

· See full US Prescribing Information for dupilumab

· MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026

Speaker disclosures:

· MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics.

· NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK.

References:

1. Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.

Uncover:

· The importance of patient phenotyping: How can biomarkers and imaging improve asthma management?

· Mucus plugging and airflow obstruction: What does the latest research reveal?

· Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling?

· The role of imaging in clinical practice: How can CT scans provide new insights into asthma care?

Speakers

Mario Castro, University of Kansas School of Medicine, United States

Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States

Disclaimers:

· This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.

· The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program

· The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits

· See full US Prescribing Information for dupilumab

· MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026

Speaker disclosures:

· MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics.

· NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK.

References:

1. Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.

Timestamps: 00:00 – Healthtech innovation 03:02 – Biohacking's future 09:20 – Three healthcare wishes

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.

Timestamps: 00:00 – Resilience Health's impact 04:30 – Gut–brain connection 12:00 – Immune optimisation

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.

Timestamps:

02:00 – Career evolution 06:45 – Holistic medicine explained

In this episode of Hema Now, Diu Nguyen joins Jonathan Sackier to discuss breakthroughs in acute myeloid leukaemia (AML) research. From RNA-binding proteins to the future of stem cell-targeted therapies, Nguyen shares the translational goals of her lab and what's on the horizon in AML diagnosis and treatment.

Timestamps:

01:20 – Quickfire Insights

03:32 – AML Breakthroughs

04:47 – Leukaemia Surprise

06:42 – Alternate Pathways

07:54 – RNA Differences

12:08 – Diagnostics Future

14:03 – RBMX Spotlight

20:21 – Targeted Therapies

27:07 – Treatment Barriers

31:32 – Three Wishes

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences.

Topics discussed include:

• Current confusion about the clinical heterogeneity within the intermediate-risk patient group
• The best way to select adequate intravesical therapy for this group
• The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy

*References

1. Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208.
2. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/
3. Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683.
4. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695.
5. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline
6. Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.